LANCASTER, Calif.–Simulations Plus, Inc. (NASDAQ: SLP – News), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration (FDA) to license the Company’s ADMET Predictor™ software.

Ron Creeley, vice president of marketing and sales for Simulations Plus, said: “We’re very pleased that the FDA’s Cardiovascular and Renal Products division has licensed our best-in-class ADMET Predictor software with all four of its modules. ADMET Predictor predicts almost 80 properties of molecules with only their molecular structure as input, including physicochemical, biopharmaceutical, metabolism, toxicity, and some activity properties. The program has been consistently ranked first in accuracy in published comparison studies with competitive programs. We’ve enjoyed our relationships with numerous FDA researchers over the years and look forward to continuing to support the part of the FDA’s Critical Path Initiative that calls for continuous improvements in modeling and simulation software for pharmaceutical research.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab™, which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.